Medical Condition News

RSS

U.K. NICE issues final draft guidance on Alimera Sciences’ ILUVIEN

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

30 Nov 2012

Article highlights Asian-American children’s variable vulnerability to obesity

Asian-American children have been at low risk for being overweight or obese compared to other racial and ethnic groups in the U.S., but that may be changing. Yet as rates of overweight and obesity rise, the risk appears to vary depending on the Asian country of origin, according to an article in Childhood Obesity, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

30 Nov 2012

New detection method can identify genetic switches associated with breast cancer

Physicians may now be better at detecting breast cancer than ever before, but much more work remains to ensure accurate diagnosis is possible and especially to assess future risk. That's why researchers from Germany have been working to develop a new test of gene action to predict cancer risk both at first diagnosis and into the future.

30 Nov 2012

Aduro completes enrollment in CRS-207 and GVAX pancreas cancer vaccine Phase 2 trial

Aduro BioTech, Inc. announces completion of enrollment in the Phase 2 clinical trial of the sequential administration of two cancer vaccines, Aduro's CRS-207 and GVAX Pancreas Cancer Vaccine, in patients with metastatic pancreatic cancer.

30 Nov 2012

FDA clears NeuroMetrix’s SENSUS Pain Management System

NeuroMetrix, Inc., a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the disposable electrode that is used in conjunction with its SENSUS device.

30 Nov 2012

Correlation between childhood intelligence and chronic widespread pain in adulthood

A UK-based study team has determined that there is a correlation between childhood intelligence and chronic widespread pain (CWP) in adulthood, according to a new study published in the December issue of PAIN.

30 Nov 2012

Novel SIRT2 inhibitor protects against neuronal damage in animal models of Huntington's

Treatment with a novel agent that inhibits the activity of SIRT2, an enzyme that regulates many important cellular functions, reduced neurological damage, slowed the loss of motor function and extended survival in two animal models of Huntington's disease.

30 Nov 2012

Scientists define key underlying process implicated in multiple sclerosis

Scientists at the Gladstone Institutes have defined for the first time a key underlying process implicated in multiple sclerosis (MS)-a disease that causes progressive and irreversible damage to nerve cells in the brain and spinal cord. This discovery offers new hope for the millions who suffer from this debilitating disease for which there is no cure.

30 Nov 2012

Tips to prevent holiday headaches

Holidays are a time for family, friends, and happy memories. But those joyful moments can be associated with stress – from marathon shopping, preparing for celebrations, and traveling. Stress and other stimuli may trigger or increase your headaches.

30 Nov 2012

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).

30 Nov 2012

Modified vitamin D receptor may reduce risk of osteoporosis

Osteoporosis, or reduced bone mineral density that can increase the risk of fractures, may affect as many as 30% of women and 12% of men worldwide. One risk factor for osteoporosis is vitamin D deficiency.

30 Nov 2012

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

30 Nov 2012

Varian's TrueBeam receives Indian AERB clearance for use in advanced radiosurgical treatments

Varian Medical Systems has received regulatory clearance from the Indian Atomic Energy Regulatory Board for the use of its unique TrueBeam High Intensity Mode for advanced radiosurgical treatments.

29 Nov 2012

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

29 Nov 2012

LP-211 compound shows promise against Fragile X syndrome

A potential new therapeutic strategy for treating Fragile X syndrome is detailed in a new report appearing in the current issue of Biological Psychiatry, from researchers led by Dr. Lucia Ciranna at University of Catania in Italy.

29 Nov 2012

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).

29 Nov 2012

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

InSite Vision Incorporated today announced that patient enrollment has been completed in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

29 Nov 2012

Longer looks: Are 'pods' the solution to our long-term care crisis?; A Liver transplant in the nick of time; Pro-life activists and the abortion drop

In November 2006, when Clara Marshall began suffering from the effects of dementia, her family moved her into ... an assisted living home in Vancouver, Wash. ... just five months into her stay, Ms. Marshall, 81, was found dead in her room apparently strangled after getting her neck caught in side rails used to prevent her from rolling out of bed.

29 Nov 2012

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.

29 Nov 2012

Study shows how PTPN22 variant linked with T1D influences susceptibility to autoimmunity

As part of their ongoing research on the role of genes in the development of type 1 diabetes, Joslin Diabetes Center scientists, in collaboration with scientists at the University of Würzburg, have demonstrated how a genetic variant associated with type 1 diabetes and other autoimmune diseases influences susceptibility to autoimmunity. The findings appear in the upcoming issue of Diabetes.

29 Nov 2012

Medical Condition News

U.K. NICE issues final draft guidance on Alimera Sciences’ ILUVIEN

Article highlights Asian-American children’s variable vulnerability to obesity

New detection method can identify genetic switches associated with breast cancer

Aduro completes enrollment in CRS-207 and GVAX pancreas cancer vaccine Phase 2 trial

FDA clears NeuroMetrix’s SENSUS Pain Management System

Correlation between childhood intelligence and chronic widespread pain in adulthood

Novel SIRT2 inhibitor protects against neuronal damage in animal models of Huntington's

Scientists define key underlying process implicated in multiple sclerosis

Tips to prevent holiday headaches

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Modified vitamin D receptor may reduce risk of osteoporosis

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Varian's TrueBeam receives Indian AERB clearance for use in advanced radiosurgical treatments

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

LP-211 compound shows promise against Fragile X syndrome

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

Longer looks: Are 'pods' the solution to our long-term care crisis?; A Liver transplant in the nick of time; Pro-life activists and the abortion drop

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Study shows how PTPN22 variant linked with T1D influences susceptibility to autoimmunity

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Latest News